Humana (HUM) Receiving Somewhat Favorable Media Coverage, Accern Reports
Media coverage about Humana (NYSE:HUM) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Humana earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the insurance provider an impact score of 46.7499264662659 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Credit Suisse Group Trims Humana Inc. (HUM) Target Price to $246.00 (americanbankingnews.com)
- Q4 2017 Earnings Estimate for Humana Inc. (HUM) Issued By Leerink Swann (americanbankingnews.com)
- Humana Inc. (HUM) to Post FY2017 Earnings of $11.69 Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- Humana cutting 2,700 jobs amid uncertainty in health care (ibj.com)
- Humana beats 3Q profit forecasts (billingsgazette.com)
Shares of Humana (HUM) opened at $244.39 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.65 and a debt-to-equity ratio of 0.35. Humana has a 1-year low of $186.25 and a 1-year high of $264.56. The stock has a market cap of $35,352.16, a price-to-earnings ratio of 21.11, a price-to-earnings-growth ratio of 1.60 and a beta of 0.91.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.18 EPS. equities research analysts forecast that Humana will post 11.62 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. Humana’s dividend payout ratio (DPR) is currently 12.59%.
A number of brokerages have recently weighed in on HUM. BMO Capital Markets boosted their target price on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday. Royal Bank Of Canada restated a “sector perform” rating and issued a $242.00 target price (down previously from $245.00) on shares of Humana in a research note on Thursday. Credit Suisse Group restated an “outperform” rating and issued a $260.00 target price (up previously from $250.00) on shares of Humana in a research note on Thursday, August 3rd. Deutsche Bank AG boosted their target price on Humana from $234.00 to $243.00 and gave the stock a “hold” rating in a research note on Monday, August 7th. Finally, Oppenheimer Holdings, Inc. boosted their target price on Humana from $236.00 to $255.00 and gave the stock an “outperform” rating in a research note on Thursday, August 3rd. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $252.81.
In other news, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now directly owns 18,042 shares in the company, valued at approximately $4,672,878. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Timothy S. Huval sold 7,803 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the transaction, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The disclosure for this sale can be found here. Insiders have sold a total of 20,660 shares of company stock valued at $5,319,600 over the last 90 days. Company insiders own 0.80% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.